 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...223224225226227228229230231232233...235236» |
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Biomarker, Enrollment open: ATOM ES: Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - May 5, 2013
P=N/A, N=100, Recruiting, Sponsor: EPS Corporation
Not yet recruiting --> Recruiting
- Enrollment open, Surgery: Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer (clinicaltrials.gov) - Apr 28, 2013
P=N/A, N=20, Recruiting, Sponsor: Alliance for Clinical Oncology Trials
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly
Enrollment change: A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver (clinicaltrials.gov) - Apr 23, 2013
P2, N=20, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Not yet recruiting --> Recruiting N=60 --> 20
- New P2 trial: A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 23, 2013
P2, N=50, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P2 trial: FFCD 1201 DEBIRI: Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study (clinicaltrials.gov) - Apr 23, 2013
P2, N=58, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- Enrollment open: A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 23, 2013
P2, N=50, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
N=60 --> 20 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly
Enrollment closed: A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver (clinicaltrials.gov) - Apr 23, 2013
P2, N=20, Active, not recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 22, 2013
P2, N=10, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion: Treatment of Acute Lymphoblastic Leukemia in Children (clinicaltrials.gov) - Apr 22, 2013
P3, N=498, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment open, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 21, 2013
P1, N=15, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- leucovorin calcium / Generic mfg.
Enrollment closed: Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer (clinicaltrials.gov) - Apr 21, 2013
P2, N=80, Active, not recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion: Complete Neoadjuvant Treatment for REctal Cancer (CONTRE) (clinicaltrials.gov) - Apr 20, 2013
P2, N=39, Completed, Sponsor: William Sikov
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P2 trial: ATOM: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Apr 18, 2013
P2, N=180, Recruiting, Sponsor: EPS Corporation
- |||||||||| HyperAcute Pancreas (algenpantucel-L) / Lumos Pharma
New P3 trial, Metastases: Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - Apr 17, 2013
P3, N=280, Recruiting, Sponsor: NewLink Genetics Corporation
- Rituxan (rituximab) / Roche
Enrollment change: Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma (clinicaltrials.gov) - Apr 16, 2013
P2, N=10, Terminated, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed N=30 --> 10
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P1 trial, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 16, 2013
P1, N=15, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- ||| andecaliximab (GS-5745) / Gilead
Enrollment open, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 16, 2013
P1, N=104, Recruiting, Sponsor: Gilead Sciences
N=30 --> 10 Not yet recruiting --> Recruiting
- foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma
Enrollment open, Combination therapy, Metastases: Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 16, 2013
P1, N=24, Recruiting, Sponsor: Prism Pharma Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Avastin (bevacizumab) / Roche
Trial completion: Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab (clinicaltrials.gov) - Apr 16, 2013
P1/2, N=70, Completed, Sponsor: University of Louisville
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| ensituximab (NEO-102) / ImmunityBio
New P1/2 trial, Metastases: QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer (clinicaltrials.gov) - Apr 15, 2013
P1/2, N=90, Recruiting, Sponsor: Precision Biologics, Inc
- Trial completion, Combination therapy, Metastases: Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer (clinicaltrials.gov) - Apr 15, 2013
P2, N=0, Completed, Sponsor: Stanford University
Recruiting --> Completed Active, not recruiting --> Completed
- Endostar (recombinant human endostatin) / Simcere
New P2 trial, Metastases: Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 14, 2013
P2, N=30, Recruiting, Sponsor: Zhejiang Cancer Hospital
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment change, Metastases: Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 11, 2013
P=N/A, N=11, Completed, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed N=30 --> 11
- || SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Enrollment closed: SIRFLOX: FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (clinicaltrials.gov) - Apr 11, 2013
P=N/A, N=518, Active, not recruiting, Sponsor: Sirtex Medical
N=30 --> 11 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 11, 2013
P=N/A, N=11, Completed, Sponsor: Fox Chase Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion, Combination therapy, Metastases: QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma (clinicaltrials.gov) - Apr 11, 2013
P2, N=155, Completed, Sponsor: Amgen
Recruiting --> Completed Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Biomarker, Enrollment open, Metastases: A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer (clinicaltrials.gov) - Apr 8, 2013
P3, N=175, Recruiting, Sponsor: AHS Cancer Control Alberta
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| pidilizumab (CT-011) / CureTech
Trial completion, IO biomarker, Metastases: Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone (clinicaltrials.gov) - Apr 8, 2013
P2, N=171, Completed, Sponsor: CureTech Ltd
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || New P3 trial, Metastases: CONKO-007: Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (clinicaltrials.gov) - Apr 7, 2013
P3, N=830, Recruiting, Sponsor: University of Erlangen-N
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Metastases: Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer (clinicaltrials.gov) - Apr 4, 2013
P2, N=100, Recruiting, Sponsor: Colorectal Cancer Institute of the Heilongjiang Academy of Medical Sciences
- ganitumab (AMG 479) / Takeda, ImmunityBio
Trial withdrawal, Metastases: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 3, 2013
P2, N=0, Withdrawn, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Completed --> Withdrawn
- ganitumab (AMG 479) / Takeda, ImmunityBio
Enrollment change, Metastases: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 3, 2013
P2, N=0, Withdrawn, Sponsor: Cancer and Leukemia Group B
Completed --> Withdrawn N=200 --> 0
- | LY2090314 / Eli Lilly
Enrollment open, Metastases, Biopsy: A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 2, 2013
P1/2, N=40, Recruiting, Sponsor: Eli Lilly and Company
N=200 --> 0 Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., levamisole / Generic mfg.
Trial completion: SWOG 9304: SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed (clinicaltrials.gov) - Apr 2, 2013
P3, N=1917, Completed, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Campath (alemtuzumab) / Sanofi
Trial termination: Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 31, 2013
P2, N=85, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Terminated; slow accrual
- | Avastin (bevacizumab) / Roche
Biomarker, New P2 trial, Combination therapy, Metastases: AC-ANGIOPREDICT: ANGIOPREDICT. ICORG 12-16, V3 (clinicaltrials.gov) - Mar 31, 2013
P2, N=224, Recruiting, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
- Trial termination, Surgery, Metastases: Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 28, 2013
P2, N=25, Terminated, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Active, not recruiting --> Terminated; slow accrual Completed --> Terminated
- New P2 trial, Metastases: Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer (clinicaltrials.gov) - Mar 28, 2013
P2, N=32, Recruiting, Sponsor: Massachusetts General Hospital
- || AL101 / Ayala Pharma
Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Mar 27, 2013
P1, N=60, Recruiting, Sponsor: Bristol-Myers Squibb
Completed --> Terminated Initiation date: Jan 2012 --> Oct 2012
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment closed, Metastases: An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Mar 27, 2013
P=N/A, N=2000, Active, not recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
Initiation date: Jan 2012 --> Oct 2012 Recruiting --> Active, not recruiting
- Enrollment open: ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis (clinicaltrials.gov) - Mar 26, 2013
P2, N=220, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Avastin (bevacizumab) / Roche
Enrollment change: 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer (clinicaltrials.gov) - Mar 25, 2013
P2, N=66, Completed, Sponsor: SCRI Development Innovations, LLC
Not yet recruiting --> Recruiting N=25 --> 66
- |||| Avastin (bevacizumab) / Roche
Trial completion: 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer (clinicaltrials.gov) - Mar 25, 2013
P2, N=66, Completed, Sponsor: SCRI Development Innovations, LLC
N=25 --> 66 Active, not recruiting --> Completed
- | New P2 trial: ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis (clinicaltrials.gov) - Mar 19, 2013
P2, N=220, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
New P2 trial: Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (clinicaltrials.gov) - Mar 18, 2013
P2, N=35, Recruiting, Sponsor: Christina Wu
- oxaliplatin / Generic mfg., irinotecan / Generic mfg., capecitabine / Generic mfg.
Enrollment open: Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma (clinicaltrials.gov) - Mar 18, 2013
P2, N=30, Recruiting, Sponsor: Medical University of South Carolina
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- ||| Avastin (bevacizumab) / Roche, onartuzumab (RG3638) / Roche
Enrollment closed, Metastases: FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 18, 2013
P2, N=194, Active, not recruiting, Sponsor: Genentech
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- NK012 / Nippon Kayaku
Enrollment closed, Combination therapy, Metastases: Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer (clinicaltrials.gov) - Mar 17, 2013
P1, N=35, Active, not recruiting, Sponsor: Nippon Kayaku Co.,Ltd.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy, Metastases: Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) (clinicaltrials.gov) - Mar 13, 2013
P1, N=180, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=140 --> 180
- Stivarga (regorafenib) / Bayer
Trial withdrawal, Metastases: Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines (clinicaltrials.gov) - Mar 11, 2013
P3, N=0, Withdrawn, Sponsor: Asan Medical Center
N=140 --> 180 Not yet recruiting --> Withdrawn